Vor Biopharma Inc.
VORNasdaq
$18.09
↑ +4.3%Jul 17 close · end-of-day
Price
1Y↓ -57.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$778.1M
Enterprise Value
$286.6M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-19.4%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$883.1M
Free Cash Flow (TTM)
-$150.7M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
587.1%
ROIC
—
Debt / Equity
—
Net Cash
$491.5M
Return 1Y
-62.0%
Company profile
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- CEO
- Bob Ang
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 140
- Headquarters
- Massachusetts
- Website
- vorbio.com
Management & directors
- Mahatme SandeshCFO
- Zuraw Qing CheChief Development Officer
Roles derived from SEC Form 4 filings.
Earnings
VOR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$5.11↓ -1.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$43.4M | -$69.0M | -$93.4M | -$126.0M | -$121.2M | -$371.6M |
| Net income | -$43.3M | -$68.9M | -$92.1M | -$117.9M | -$116.9M | -$696.0M |
| Diluted EPS | — | -$2.10 | -$2.33 | -$1.75 | -$34.03 | -$70.50 |
| Operating cash flow | -$36.3M | -$69.1M | -$85.1M | -$100.3M | -$99.7M | -$142.7M |
| Free cash flow | -$40.5M | -$73.0M | -$93.6M | -$101.4M | -$99.9M | -$143.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$29.0M | -$28.5M | -$31.3M | -$33.3M | -$274.3M | -$28.1M | -$36.0M | -$35.2M |
| Net income | -$27.8M | -$27.6M | -$30.7M | -$32.5M | -$1.6B | -$812.7M | $1.7B | -$219.6M |
| Diluted EPS | -$0.41 | -$8.05 | -$25.12 | -$5.21 | -$12.56 | -$121.63 | $68.90 | -$5.11 |
| Operating cash flow | -$21.8M | -$23.3M | -$24.1M | -$31.1M | -$35.2M | -$53.7M | -$22.8M | -$38.2M |
| Free cash flow | -$21.9M | -$23.3M | -$24.1M | -$31.3M | -$35.3M | -$53.9M | -$23.1M | -$38.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 2, 2026
Jun 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-22 | RA CAPITAL MANAGEMENT, LLC | Sale | 165,150 | $15.77 | $2.6M | filing |
| 2026-04-20 | RA CAPITAL MANAGEMENT, LLC | Sale | 171,963 | $15.77 | $2.7M | filing |
| 2026-04-17 | RA CAPITAL MANAGEMENT, LLC | Sale | 458,411 | $16.28 | $7.5M | filing |
| 2026-04-15 | RA CAPITAL MANAGEMENT, LLC | Sale | 53,644 | $16.01 | $858,840.44 | filing |
| 2026-04-14 | RA CAPITAL MANAGEMENT, LLC | Sale | 153,735 | $15.97 | $2.5M | filing |
| 2026-04-13 | RA CAPITAL MANAGEMENT, LLC | Sale | 530,610 | $16.15 | $8.6M | filing |
| 2026-04-10 | RA CAPITAL MANAGEMENT, LLC | Sale | 828 | $15.75 | $13,041.00 | filing |
| 2026-04-09 | RA CAPITAL MANAGEMENT, LLC | Sale | 135,201 | $16.59 | $2.2M | filing |
| 2026-04-08 | RA CAPITAL MANAGEMENT, LLC | Sale | 353,242 | $16.32 | $5.8M | filing |
| 2026-04-08 | RA CAPITAL MANAGEMENT, LLC | Sale | 130,862 | $16.91 | $2.2M | filing |
| 2026-04-06 | RA CAPITAL MANAGEMENT, LLC | Sale | 537,754 | $16.51 | $8.9M | filing |
| 2026-04-06 | RA CAPITAL MANAGEMENT, LLC | Sale | 44,728 | $17.31 | $774,241.68 | filing |
| 2026-04-06 | RA CAPITAL MANAGEMENT, LLC | Sale | 6,775 | $18.50 | $125,337.50 | filing |
| 2026-04-02 | RA CAPITAL MANAGEMENT, LLC | Sale | 258,475 | $18.23 | $4.7M | filing |
| 2026-04-02 | RA CAPITAL MANAGEMENT, LLC | Sale | 1,525 | $19.06 | $29,066.50 | filing |
| 2025-12-18 | RA CAPITAL MANAGEMENT, LLC | Award | 4,625,346 | $10.81 | $50.0M | filing |
| 2025-12-05 | Mahatme Sandesh· CFO | D | 694,137 | $0.00 | $0.00 | filing |
| 2025-10-30 | RA CAPITAL MANAGEMENT, LLC | Sale | 24,579 | $25.12 | $617,424.48 | filing |
| 2025-10-29 | RA CAPITAL MANAGEMENT, LLC | Sale | 251,518 | $25.22 | $6.3M | filing |
| 2025-10-28 | RA CAPITAL MANAGEMENT, LLC | Sale | 87,828 | $27.10 | $2.4M | filing |
| 2025-10-28 | RA CAPITAL MANAGEMENT, LLC | Sale | 36,483 | $28.18 | $1.0M | filing |
| 2025-10-27 | RA CAPITAL MANAGEMENT, LLC | Sale | 90,941 | $28.12 | $2.6M | filing |
| 2025-10-24 | RA CAPITAL MANAGEMENT, LLC | Sale | 53,345 | $28.01 | $1.5M | filing |
| 2025-10-23 | RA CAPITAL MANAGEMENT, LLC | Sale | 76,880 | $28.01 | $2.2M | filing |
| 2025-10-21 | RA CAPITAL MANAGEMENT, LLC | Sale | 25,027 | $28.11 | $703,508.97 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.